Do analysts rate HOWL or BLRX?

Werewolf Therapeutics presently has a consensus target price of $4.00, suggesting a potential upside of 334.74%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Werewolf Therapeutics is more favorable than BioLineRx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Werewolf Therapeutics 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.43 BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer HOWL or BLRX?

In the previous week, Werewolf Therapeutics had 1 more articles in the media than BioLineRx. MarketBeat recorded 2 mentions for Werewolf Therapeutics and 1 mentions for BioLineRx. Werewolf Therapeutics' average media sentiment score of 0.50 beat BioLineRx's score of 0.00 indicating that Werewolf Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Werewolf Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioLineRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer TVGN or BLRX?

Tevogen Bio currently has a consensus price target of $100.00, suggesting a potential upside of 1,385.88%. Given Tevogen Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Tevogen Bio is more favorable than BioLineRx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tevogen Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TVGN or BLRX more profitable?

Tevogen Bio has a net margin of 0.00% compared to BioLineRx's net margin of -502.08%. Tevogen Bio's return on equity of 0.00% beat BioLineRx's return on equity. Company Net Margins Return on Equity Return on Assets Tevogen Bio N/A N/A -468.32% BioLineRx -502.08% -34.80% -18.27%

Do analysts recommend BLRX or MGX?

Metagenomi has a consensus target price of $6.00, suggesting a potential upside of 509.32%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts plainly believe Metagenomi is more favorable than BioLineRx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Metagenomi 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Is BLRX or MGX more profitable?

Metagenomi has a net margin of -384.61% compared to BioLineRx's net margin of -502.08%. BioLineRx's return on equity of -34.80% beat Metagenomi's return on equity. Company Net Margins Return on Equity Return on Assets BioLineRx -502.08% -34.80% -18.27% Metagenomi -384.61% -63.65% -44.52%

Does the media prefer BLRX or MGX?

In the previous week, Metagenomi had 1 more articles in the media than BioLineRx. MarketBeat recorded 2 mentions for Metagenomi and 1 mentions for BioLineRx. BioLineRx's average media sentiment score of 0.00 equaled Metagenomi'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioLineRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BLRX or PDSB?

PDS Biotechnology has a consensus price target of $9.00, suggesting a potential upside of 745.07%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe PDS Biotechnology is more favorable than BioLineRx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PDS Biotechnology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Does the media prefer BLRX or PDSB?

In the previous week, PDS Biotechnology had 1 more articles in the media than BioLineRx. MarketBeat recorded 2 mentions for PDS Biotechnology and 1 mentions for BioLineRx. BioLineRx's average media sentiment score of 0.00 equaled PDS Biotechnology'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioLineRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PDS Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend BLRX or CELU?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Celularity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BLRX or CELU more profitable?

Celularity has a net margin of -374.87% compared to BioLineRx's net margin of -502.08%. Celularity's return on equity of 0.00% beat BioLineRx's return on equity. Company Net Margins Return on Equity Return on Assets BioLineRx -502.08% -34.80% -18.27% Celularity -374.87% N/A -64.45%

Does the media prefer BLRX or CELU?

In the previous week, BioLineRx and BioLineRx both had 1 articles in the media. Celularity's average media sentiment score of 0.12 beat BioLineRx's score of 0.00 indicating that Celularity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioLineRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Celularity 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

BioLineRx (BLRX) Competitors

$2.20 +0.01 (+0.23%)

As of 12:00 PM Eastern

Compare

BLRX vs. HOWL, TVGN, MGX, PDSB, and CELU

Should you buy BioLineRx stock or one of its competitors? BioLineRx's main competitors and comparable companies include Werewolf Therapeutics (HOWL), Tevogen Bio (TVGN), Metagenomi (MGX), PDS Biotechnology (PDSB), and Celularity (CELU). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioLineRx compare to Werewolf Therapeutics?

Werewolf Therapeutics (NASDAQ:HOWL) and BioLineRx (NASDAQ:BLRX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 1.6% of BioLineRx shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by company insiders. Comparatively, 1.1% of BioLineRx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Werewolf Therapeutics presently has a consensus target price of $4.00, suggesting a potential upside of 334.74%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Werewolf Therapeutics is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Werewolf Therapeutics has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, BioLineRx has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market.

In the previous week, Werewolf Therapeutics had 1 more articles in the media than BioLineRx. MarketBeat recorded 2 mentions for Werewolf Therapeutics and 1 mentions for BioLineRx. Werewolf Therapeutics' average media sentiment score of 0.50 beat BioLineRx's score of 0.00 indicating that Werewolf Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Werewolf Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioLineRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioLineRx has lower revenue, but higher earnings than Werewolf Therapeutics. BioLineRx is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	23.79	-$60.82M	-$0.76	N/A
BioLineRx	$1.18M	9.28	-$1.17M	-$1.69	N/A

Werewolf Therapeutics has a net margin of 0.00% compared to BioLineRx's net margin of -502.08%. BioLineRx's return on equity of -34.80% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-166.99%	-59.88%
BioLineRx	-502.08%	-34.80%	-18.27%

Summary

Werewolf Therapeutics beats BioLineRx on 13 of the 17 factors compared between the two stocks.

How does BioLineRx compare to Tevogen Bio?

Tevogen Bio (NASDAQ:TVGN) and BioLineRx (NASDAQ:BLRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Tevogen Bio currently has a consensus price target of $100.00, suggesting a potential upside of 1,385.88%. Given Tevogen Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Tevogen Bio is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Tevogen Bio has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, BioLineRx has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market.

In the previous week, BioLineRx had 1 more articles in the media than Tevogen Bio. MarketBeat recorded 1 mentions for BioLineRx and 0 mentions for Tevogen Bio. Tevogen Bio's average media sentiment score of 0.00 equaled BioLineRx'saverage media sentiment score.

Company	Overall Sentiment
Tevogen Bio	Neutral
BioLineRx	Neutral

BioLineRx has higher revenue and earnings than Tevogen Bio. Tevogen Bio is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.63	N/A
BioLineRx	$1.18M	9.28	-$1.17M	-$1.69	N/A

1.6% of BioLineRx shares are held by institutional investors. 65.6% of Tevogen Bio shares are held by insiders. Comparatively, 1.1% of BioLineRx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Tevogen Bio has a net margin of 0.00% compared to BioLineRx's net margin of -502.08%. Tevogen Bio's return on equity of 0.00% beat BioLineRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-468.32%
BioLineRx	-502.08%	-34.80%	-18.27%

Summary

BioLineRx beats Tevogen Bio on 8 of the 13 factors compared between the two stocks.

How does BioLineRx compare to Metagenomi?

BioLineRx (NASDAQ:BLRX) and Metagenomi (NASDAQ:MGX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Metagenomi has a net margin of -384.61% compared to BioLineRx's net margin of -502.08%. BioLineRx's return on equity of -34.80% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-502.08%	-34.80%	-18.27%
Metagenomi	-384.61%	-63.65%	-44.52%

BioLineRx has higher earnings, but lower revenue than Metagenomi. BioLineRx is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	9.28	-$1.17M	-$1.69	N/A
Metagenomi	$25.21M	1.48	-$87.87M	-$2.49	N/A

1.6% of BioLineRx shares are held by institutional investors. 1.1% of BioLineRx shares are held by company insiders. Comparatively, 12.5% of Metagenomi shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Metagenomi has a consensus target price of $6.00, suggesting a potential upside of 509.32%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts plainly believe Metagenomi is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Metagenomi had 1 more articles in the media than BioLineRx. MarketBeat recorded 2 mentions for Metagenomi and 1 mentions for BioLineRx. BioLineRx's average media sentiment score of 0.00 equaled Metagenomi'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLineRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Metagenomi	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioLineRx has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market. Comparatively, Metagenomi has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

Summary

Metagenomi beats BioLineRx on 9 of the 16 factors compared between the two stocks.

How does BioLineRx compare to PDS Biotechnology?

BioLineRx (NASDAQ:BLRX) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

BioLineRx has higher revenue and earnings than PDS Biotechnology. PDS Biotechnology is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	9.28	-$1.17M	-$1.69	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.64	N/A

PDS Biotechnology has a consensus price target of $9.00, suggesting a potential upside of 745.07%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe PDS Biotechnology is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

PDS Biotechnology has a net margin of 0.00% compared to BioLineRx's net margin of -502.08%. BioLineRx's return on equity of -34.80% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-502.08%	-34.80%	-18.27%
PDS Biotechnology	N/A	-708.18%	-136.50%

BioLineRx has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market.

1.6% of BioLineRx shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 1.1% of BioLineRx shares are held by company insiders. Comparatively, 8.4% of PDS Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, PDS Biotechnology had 1 more articles in the media than BioLineRx. MarketBeat recorded 2 mentions for PDS Biotechnology and 1 mentions for BioLineRx. BioLineRx's average media sentiment score of 0.00 equaled PDS Biotechnology'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLineRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PDS Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

PDS Biotechnology beats BioLineRx on 8 of the 14 factors compared between the two stocks.

How does BioLineRx compare to Celularity?

BioLineRx (NASDAQ:BLRX) and Celularity (NASDAQ:CELU) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

In the previous week, BioLineRx and BioLineRx both had 1 articles in the media. Celularity's average media sentiment score of 0.12 beat BioLineRx's score of 0.00 indicating that Celularity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLineRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Celularity	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by company insiders. Comparatively, 17.3% of Celularity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Celularity has a net margin of -374.87% compared to BioLineRx's net margin of -502.08%. Celularity's return on equity of 0.00% beat BioLineRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-502.08%	-34.80%	-18.27%
Celularity	-374.87%	N/A	-64.45%

BioLineRx has higher earnings, but lower revenue than Celularity. BioLineRx is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	9.28	-$1.17M	-$1.69	N/A
Celularity	$26.55M	1.60	-$91.72M	-$2.73	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Celularity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BioLineRx has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market. Comparatively, Celularity has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market.

Summary

Celularity beats BioLineRx on 7 of the 12 factors compared between the two stocks.

Get BioLineRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLRX vs. The Competition

Export

Metric	BioLineRx	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.98M	$3.75B	$7.05B	$13.29B
Dividend Yield	N/A	3.66%	2.53%	16.47%
P/E Ratio	-1.30	13.63	275.25	25.94
Price / Sales	9.31	1,173.54	571.70	85.02
Price / Cash	N/A	118.37	77.41	52.81
Price / Book	0.41	16.15	10.82	6.24
Net Income	-$1.17M	-$22.65M	$3.50B	$382.01M
7 Day Performance	-6.17%	-4.50%	-2.58%	-1.66%
1 Month Performance	-14.86%	-13.64%	-8.03%	-5.86%
1 Year Performance	-49.89%	7.48%	2.31%	-1.93%

BioLineRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLRX BioLineRx	0.2995 of 5 stars	$2.21 +0.2%	N/A	-50.5%	$10.98M	$1.18M	N/A	24	News Coverage Gap Up
HOWL Werewolf Therapeutics	3.0129 of 5 stars	$0.91 -2.2%	$4.00 +339.6%	-52.3%	$44.23M	$1.88M	N/A	14	News Coverage Analyst Upgrade
TVGN Tevogen Bio	1.5133 of 5 stars	$6.75 -0.1%	$100.00 +1,381.5%	-81.9%	$43.94M	N/A	N/A	3	Gap Up
MGX Metagenomi	3.2212 of 5 stars	$1.13 -0.9%	$6.00 +431.0%	-66.6%	$42.69M	$25.21M	N/A	113
PDSB PDS Biotechnology	1.793 of 5 stars	$0.74 -3.0%	$9.00 +1,111.5%	+10.5%	$41.58M	N/A	N/A	21	Analyst Upgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BLRX) was last updated on 10/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioLineRx (BLRX) Competitors

BLRX vs. HOWL, TVGN, MGX, PDSB, and CELU

How does BioLineRx compare to Werewolf Therapeutics?

Summary

How does BioLineRx compare to Tevogen Bio?

Summary

How does BioLineRx compare to Metagenomi?

Summary

How does BioLineRx compare to PDS Biotechnology?

Summary

How does BioLineRx compare to Celularity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLRX vs. The Competition

BioLineRx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioLineRx (BLRX) Competitors

BLRX vs. HOWL, TVGN, MGX, PDSB, and CELU

How does BioLineRx compare to Werewolf Therapeutics?

Do insiders & institutionals hold more shares of HOWL or BLRX?

Do analysts rate HOWL or BLRX?

Which has more volatility & risk, HOWL or BLRX?

Does the media prefer HOWL or BLRX?

Which has stronger earnings & valuation, HOWL or BLRX?

Is HOWL or BLRX more profitable?

Summary

How does BioLineRx compare to Tevogen Bio?

Do analysts prefer TVGN or BLRX?

Which has more risk and volatility, TVGN or BLRX?

Does the media prefer TVGN or BLRX?

Which has higher earnings & valuation, TVGN or BLRX?

Do institutionals & insiders have more ownership in TVGN or BLRX?

Is TVGN or BLRX more profitable?

Summary

How does BioLineRx compare to Metagenomi?

Is BLRX or MGX more profitable?

Which has better earnings and valuation, BLRX or MGX?

Do institutionals and insiders hold more shares of BLRX or MGX?

Do analysts recommend BLRX or MGX?

Does the media prefer BLRX or MGX?

Which has more volatility and risk, BLRX or MGX?

Summary

How does BioLineRx compare to PDS Biotechnology?

Which has higher valuation & earnings, BLRX or PDSB?

Do analysts rate BLRX or PDSB?

Is BLRX or PDSB more profitable?

Which has more risk & volatility, BLRX or PDSB?

Do institutionals and insiders hold more shares of BLRX or PDSB?

Does the media prefer BLRX or PDSB?

Summary

How does BioLineRx compare to Celularity?

Does the media prefer BLRX or CELU?

Do insiders & institutionals hold more shares of BLRX or CELU?

Is BLRX or CELU more profitable?

Which has better valuation & earnings, BLRX or CELU?

Do analysts recommend BLRX or CELU?

Which has more volatility & risk, BLRX or CELU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLRX vs. The Competition

BioLineRx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools